Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years

Gynecol Oncol. 2019 Jun;153(3):479-486. doi: 10.1016/j.ygyno.2019.02.020. Epub 2019 Mar 22.

Abstract

The Gynecologic Oncology Group (GOG), now part of the NRG Oncology network since the re-alignment of the National Clinical Trials Network in 2014, has played a fundamental role in creating the standard of care for women with ovarian cancer. GOG/NRG Oncology has had a series of achievements that have contributed to how we treat this disease; the approval of bevacizumab in frontline therapy, defining the role of intraperitoneal chemotherapy, optimal chemotherapy for early stage disease and the role of surgery in primary and recurrent disease management. Going forward, GOG/NRG Oncology is positioned to meet the ever changing knowledge that we have about the molecular background of this disease and the expanding repertoire of drugs/interventions in development.

Keywords: Chemotherapy; Clinical trials; Ovarian cancer; Recurrent disease.

Publication types

  • Review

MeSH terms

  • Administration, Intravenous
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / administration & dosage
  • Carboplatin / administration & dosage
  • Cisplatin / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Cytoreduction Surgical Procedures
  • Female
  • Humans
  • Infusions, Parenteral
  • Maintenance Chemotherapy
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm Staging
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*
  • Paclitaxel / therapeutic use
  • Randomized Controlled Trials as Topic*
  • Standard of Care*

Substances

  • Bevacizumab
  • Cyclophosphamide
  • Carboplatin
  • Paclitaxel
  • Cisplatin